Evidence map›Paper›PMID 41593588›Full record

ReviewBMC oral health2026

Oral lichenoid lesions in association with immunotherapies: a report of two cases and a review of published work.

Fan Huang, Yuefeng Song, Xiang Wang, Wenmei Wang, Ning Duan

Abstract readCase ReportsReview
In one paragraph

Review in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fan HuangNanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing, China.
Yuefeng SongNanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing, China.
Xiang WangNanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing, China.
Wenmei WangNanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing, China.
Ning DuanNanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing, China. smallbird123@sina.com.

Funding

the Nanjing Medical Science and Technique Development Foundation ZKX17033the Nanjing Stomatological Hospital 3456 backbone talent plan 0222C103the National Natural Scientific Foundation of China 82571105the Project of Jiangsu Provincial Medical Youth Talent QNRC2016118
6 · The paper itself

Abstract

backgroundA variety of drug-induced oral lichenoid lesions (OLLs) have been extensively reported in the literature, but the diagnosis and recognition of OLLs remain challenging for clinicians. To date, a wide range of drugs, including anti-inflammatory drugs, antihypertensives, antibiotics and others, have been suggested to cause OLLs with different presentations. To the best of our knowledge, immunotherapies are becoming increasingly preferred treatments for systemic diseases. At the same time, oral adverse events, including OLLs due to immunotherapies, are not widely appreciated. CASE PRESENTATION: We present two cases of OLLs in patients with ankylosing spondylitis and follicular lymphoma in whom different immunotherapies, including sulfasalazine and obinutuzumab, were used. The oral lesions presented reticular, atrophic, and ulcerated patterns. The patients' oral lesions improved after the administration of glucocorticoid therapy and the cessation of immunoregulatory treatment.

conclusionThis article describes two rare and representative cases related to OLLs induced by immunotherapies to update our knowledge of the drugs used by patients and improve the management, recognition and reporting of oral adverse events.

Indexed as

Antibodies, Monoclonal, HumanizedImmunotherapyLichenoid EruptionsSulfasalazineFemaleHumansLymphoma, FollicularMaleMiddle AgedAntibodies, Monoclonal, HumanizedobinutuzumabSulfasalazineImmunotherapiesObinutuzumabOral adverse eventsOral lichenoid lesionsSulfasalazine

Identifiers

PMID41593588
PMCPMC12879319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.